Healthcare has traditionally relied on treating patients according to the characteristics of their disease. Personalised medicine is moving this approach towards a more individualised model, using information about a person's genetic and molecular characteristics, clinical history and other health data to help guide prevention, diagnosis and treatment.
The World Health Organization describes precision medicine as the use of clinical, molecular, genomic and other health-related information to inform healthcare decisions while taking individual differences into account. In May 2026, the World Health Assembly endorsed a resolution supporting the responsible and equitable integration of precision medicine into health systems.
From Standardised Care to Individualised Decisions
Patients with the same diagnosis do not necessarily respond to treatment in the same way.
Their genetics, disease characteristics, lifestyle, environment and previous treatment can all influence how a condition develops or how an individual responds to a particular therapy.
Personalised medicine aims to use this additional information to help clinicians make more informed decisions about which prevention, diagnostic or treatment approach may be appropriate for an individual patient.
This does not mean that every patient receives a completely different treatment. Rather, it provides additional information that can help healthcare professionals determine which option is most suitable.
The Role of Genomics
Genomics is one of the foundations of personalised medicine.
By studying a person's genetic information, healthcare professionals and researchers can identify genetic characteristics associated with disease risk, treatment response or medication response.
WHO identifies applications of genomics across risk assessment, diagnosis, treatment selection, disease monitoring and drug development. Pharmacogenomics, for example, examines how genomic differences can influence an individual's response to medicines.
This creates opportunities to move towards treatment decisions that are increasingly informed by the biological characteristics of the individual patient.
Personalised Medicine in Cancer Care
Oncology is one of the clearest examples of how personalised medicine is being applied.
Cancer cells can contain genetic and molecular changes that influence how a tumour develops and how it responds to treatment. Biomarker testing can identify some of these changes and help doctors determine whether particular targeted treatments may be appropriate.
For example, targeted cancer therapies may be designed to act on specific proteins or molecular changes that help cancer cells grow and spread. This is one of the foundations of precision oncology.
Importantly, personalised cancer treatment does not mean that genomic testing automatically determines the treatment. Results must be interpreted alongside the patient's diagnosis, disease stage, overall health and other clinical factors.
Pharmacogenomics: Matching Medicines to the Patient
People can respond differently to the same medicine.
Pharmacogenomics studies how genetic differences can affect an individual's response to medicines. This area of precision medicine may help healthcare professionals understand why a particular medicine may work differently between patients or why some individuals may be more susceptible to certain adverse effects.
As genomic knowledge develops, pharmacogenomics may increasingly contribute to decisions around medication selection and dosing for appropriate patients.
Personalised Prevention
Personalised medicine is not limited to treating an existing disease.
Genetic and other health information can also contribute to understanding an individual's risk of developing certain conditions. This creates opportunities for more targeted prevention, screening and monitoring where clinically appropriate.
The broader direction is towards healthcare that can identify risk earlier and determine which interventions may be most relevant to the individual.
The Importance of Data
Personalised medicine depends on information.
Genomic data, clinical records, laboratory results, imaging, biomarkers and other health information can all contribute to understanding an individual's healthcare needs.
But using this information responsibly requires strong safeguards. WHO highlights the importance of privacy, transparency, ethical governance, data security and equitable access when genomic information is collected and used.
This is particularly important because genomic information can be highly sensitive and may have implications beyond the individual patient.
Where Bluedot Fits
Personalised medicine is ultimately valuable when advanced information can be translated into an appropriate healthcare pathway.
Bluedot Medical Assistance supports the coordination that connects patients, medical teams, hospitals and healthcare stakeholders.
When a patient requires specialist assessment or treatment, our role can include coordinating medical documentation with appropriate healthcare providers, facilitating communication with specialist teams and supporting treatment pathways locally or internationally.
For patients considering specialist treatment abroad, this coordination can help ensure that relevant medical information is available to the receiving hospital before treatment arrangements are made.
Bluedot does not determine whether genomic testing, personalised treatment or a particular therapy is appropriate. Those decisions remain with qualified medical professionals based on the patient's individual circumstances.
The Future of Personalised Healthcare
Personalised medicine is developing alongside advances in genomics, molecular diagnostics, pharmacogenomics, data science and digital health. WHO's 2026 precision medicine resolution recognises these technologies as part of a broader shift towards more targeted, predictive and preventive healthcare.
The challenge is ensuring that these advances are not only scientifically effective but also clinically appropriate, ethically governed and accessible to the patients who may benefit from them.